Research programme: diabetes therapy - Crucell

Drug Profile

Research programme: diabetes therapy - Crucell

Alternative Names: diabetes therapy research programme - Crucell

Latest Information Update: 26 Jan 2005

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Crucell; University Medical Center Utrecht
  • Class Monoclonal antibodies; Proteins; Vaccines
  • Mechanism of Action Islet amyloid polypeptide inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Type 2 diabetes mellitus

Most Recent Events

  • 26 Jan 2005 Discontinued - Preclinical for Type-2 diabetes mellitus in Netherlands (unspecified route)
  • 21 May 2001 Preclinical development for Type-2 diabetes mellitus in Netherlands (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top